ClinicalTrials.gg
WithdrawnNCT03929835Updated Aug 4, 2021

Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa

A Phase 2 interventional study of Cannabis oil and Placebo in Hidradenitis Suppurativa, sponsored by TO Pharmaceuticals. Withdrawn at 1 site in Israel. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-08-04.

Sponsored by TO Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was withdrawn
withdrawn due to COVID-19

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Hidradenitis Suppurativa with a site in Israel — 1 open to participants now, 3 under way, 2 of them phase 3. Hidradenitis Suppurativa · Israel.

Enrollment
10th of 10
0 · median 527
Started
2020
with 3 others
Phase 2
2 of 11
1 open now
Registered
4th of 11
by date
Lead sponsor
1 of 11
TO Pharmaceuticals

Among the 11 studies in Hidradenitis Suppurativa with a site in Israel, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2020, is one of 2 in phase 2, and was the 4th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

1 of the 11 studies in Hidradenitis Suppurativa with a site in Israel is open now. Recruiting first, the newest first:

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Hidradenitis Suppurativa with a site in Israel, or all of them as a file.
02

Study summary

Hidradenitis Suppurativa (HS), is a chronic skin disease, manifested as inflamed areas of hair follicles around apocrine sweat glands found in areas most commonly the axillae, inguinal and anogenital regions. Patients experience great deal of physical pain as well as profound psychological problems. HS patients may also be prone to health complications and diseases. Treatment to date is limited and consist mainly of antibiotic administration and novel biological drug with up to 40% efficiency. Recently it was shown that cannabinoids reduces the folliculo pilosebaceous activity, most likely due to activating arachnoiditis, lipostat , anti-proliferative and anti-inflammatory agents and reduce inflammation inducing cytokines.

Read the detailed description

Forty participants will be recruited over two years. After determine eligibility by examining the study criteria for inclusion and exclusion, the patient will be asked to sign the informed consent form.

The YAKAR form of medical cannabis license application and a confidentiality waiver form will be sent to the YAKAR. The physician will explain to the patients that his/her participation in the trial can be terminated at any time and will explain the medical license conditions: It is absolutely forbidden to:

  • Use cannabis in the presence of minors or in public
  • Drive under the influence of cannabis
  • The participant shall take measures to prevent the theft of cannabis and inform the Investigator and the YAKAR of an attempt to steal or lose of cannabis.

When the patient license arrives, the patient will be scheduled an appointment for the first visit of the trial at the hospital. Tikun-Olam will be informed and asked to supply the patient product on the visit day. The copy of the patient's license will be included into the trial source documents.

The participants will be randomly assigned in a 1:1 ratio to receive Avidekel oil or placebo oil. Patients will receive the oils as drops applied under the tongue 3 times a day.

The duration of study participation for each subject is expected to be 12 weeks (84 days), about 4 weeks from visit 0 until receiving the license and 8 weeks trial,of which, six weeks of dose titration. Over the course of twelve weeks, four visits will be conducted and there will be 3 telephone evaluations. During first visit screening and enrolment will be conducted. The second visit will take place four weeks later where patients will receive the oils and start the trial, followed by a phone call evaluation at day 5-7 after starting the treatment and at week 2±2 days. Than a visit approximately four weeks later, following another phone call evaluation at week 5±2 days from treatment beginning, F Last visit will be conducted at week 8±3 days. In each visit, the relevant variables will be collected (Please refer to Table 3. Schedule of events). At the end of the eight-week experiment, patients from the treatment and control groups will be given the option to use the Avidekel oil for a period of one year. First, all the patients will use the drug in the open label phase for 8 weeks, during this period 3 phone calls and 2 visits in the hospital will be conducted, using PI-NRS and HS-PGA score to evaluate treatment success. Patients who will have at least 1 point reduction on the HS-PGA score will be permitted to continue to the 1 year follow-up. During that period 2 visits, six months and one year, will be conducted and the relevant variables will be collected (see Table 3). All visits will take place at the hospital.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Cannabis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects >20.
  • Subjects who are diagnosed with moderate to severe Hidradenitis Suppurativa for at least 12 months prior to screening.
  • Written from participant.
  • For women, consent to avoid pregnancy during the trial.
  • Consent to avoid driving during the influence of cannabis

Exclusion criteria

Exclusion Criteria:

  • Patients receiving any of the following medications: Astemizole, Cisapride, Pimozide or Terfenadine.
  • Patients with severe heart disease.
  • Subjects suffering from Epilepsy.
  • Subjects suffering from anxiety disorder.
  • Subjects who had psychotic condition in the past OR suffering from psychosis.
  • Schizophrenia OR family history of Schizophrenia OR any other mental disorder.
  • Significant psychiatric inheritance in a first-degree family member, especially in patients under 30.
  • Pregnancy or intention to become pregnant during the study period
  • Subjects with any other condition, which in the judgment of the investigator would prevent the subject from completing the study.
  • Subjects suffering from chronic pain that does not necessarily is an outcome of the HS (Fibromyalgia, slipped disc).
  • Any condition that the Investigator believes would interfere with the intent of the study or would make participation not in the best interest of the patient.
  • Patients suffering from alcohol and/or substance abuse
  • Surgery within 30 days prior to screening or scheduled surgery during the study period.
  • Current participation in another drug or device clinical trial, or participation in such a clinical trial
  • Lack of cooperation until the end of the study period.
  • Patients with medical cannabis license
  • Patients suffering from kidney disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Avidekel Oil

    The cannabis oil, sort T1/C20 CBD as categorized by the MOH guidelines will be made from Avidekel strain and olive oil extract. Avidekel oil contains Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.

    Drug: Cannabis oil

  • Placebo comparator
    Placebo

    Patients in the control group will receive placebo oil containing olive oil and Chlorophyll.

    Drug: Placebo

Interventions

  • T1/C20 CBD

    Also known as: Avidekel Oil

  • DrugPlacebo

    Olive oil with chlorophyl

    Also known as: Olive oil with chlorophyl

06

What researchers measure

Primary outcomes

  1. Clinical response

    1 point reduction in HS-PGA score in treatment vs. control at week 8

    Time frame: From Week 0 to Week 8

Secondary outcomes

  1. Safety: Participants experiencing Adverse Events (AE's) or Serious Adverse Events (SAE's)

    Participants experiencing Adverse Events (AE's) or Serious Adverse Events (SAE's)

    Time frame: Week 3, Week 6, six months and 12 months

  2. Efficacy: Hidradenitis suppurativa Severity Index (HSSI)

    Hidradenitis suppurativa Severity Index (HSSI)

    Time frame: 6 weeks, six months and 12 months

  3. Clinical response

    Hidradenitis Suppurativa Clinical Response (HiSCR)

    Time frame: 6 weeks of treatment

  4. Changes from baseline

    Dermatology Quality of Life Index (DLQI)

    Time frame: From Week 0 to Week 6, six months and 12 months

  5. Efficacy on pain levels: VAS pain scale

    VAS pain scale 11-point numerical pain rating scale

    Time frame: From Week 0 to Week 8, 16 weeks, six months and 12 months

07

Study locations

1 site
  • Haemek Hospital
    Afula, Israel
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2020; primary completion for Sep 2022, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2019
First posted
Apr 29, 2019
StartEst.
Sep 1, 2020
Primary completionEst.
Sep 1, 2022
CompletionEst.
Sep 1, 2022
Last update
Aug 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03929835
Lead sponsor
TO Pharmaceuticals
Responsible party
Sponsor
First posted
Apr 29, 2019
Start date
Sep 1, 2020 (estimated)
Primary completion
Sep 1, 2022 (estimated)
Completion
Sep 1, 2022 (estimated)
Last update
Aug 4, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabis sativa flowering TOP

Start the discussion